FAST Congress

 

Personalized Medicine 
  • Drug Diagnostic Co-Development
  • Targeted Cancer Therapy

Translational Cancer Medicine 
  • Circulating Tumor Cells
  • Cancer Stem Cells
Biomarker Development
  • Protein Biomarkers
  • Biomarker Data Analysis
  • Cancer Biomarkers
Adaptive Clinical Trials
  • Implementation of Adaptive Clinical Trials
  • Adaptive Trial Designs for Proof-of-Concept and Dose Finding
Diagnostic Development
  • Companion Diagnostics
Pre-Conference Events

Short Course: Fit-For-Purpose Biomarker Assay Development and Validation 

Executive Think Tank: Strategies for Drug-Diagnostic Co-Development 

 

Featured Speakers

Eric Green
Eric Green
Director
NHGRI NIH

Ruth March
Ruth March
Leader
Personalized Healthcare
AstraZeneca

Zivana Tezak
Zivana Težak
Associate Director
Personalized Medicine
CDRH, FDA

Andrea Lauber
Andrea Lauber
Head, Pharmacodiagnostics
Strategic Transactions
Briston-Myers Squibb Co.

Thomas Ried
Thomas Ried
Chief
Cancer Genomics
National Cancer Institute

Edward Abrahams
Edward Abrahams
Executive Director
Personalized Medicine
Coalition

 

Event Highlights:

Event HighlightsNETWORK with 500+ delegates from 275+ organizations, representing 20+ countries.
LEARN from 100+ presentations, 50+ posters, and 30+ exhibits.
ACCESS five tracks, covering personalized medicine, cancer, biomarkers, diagnostics, and clinical trials.

What’s New in 2010:

  • Expanded coverage of personalized medicine models and bridging drug-diagnostic development
  • In addition to circulating tumor cells, the coverage of cancer research includes cancer stem cells, translation of the cancer genome, and cancer biomarkers
  • The new track on Diagnostic Development covers the latest advances in molecular diagnostics
  • Continued from 2009 are the long-running meetings on biomarker development and
    adaptive clinical trial designs